Adagene Inc. (ADAG)

Pharmaceutical Preparations · market cap $179M · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Adagene Inc. (ADAG) is a small-cap pharmaceutical company (~$233M market cap, 138 employees) with a pipeline centered on ADG126, an oncology asset in Phase 2 development for advanced/metastatic solid tumors. The company's near-term catalysts are concentrated in a single Phase 2 readout estimated around October 31, 2026, which the internal scoring rates 7/10 in importance.

The catalyst path

2026-10-31 (est.)Phase 2 · ADG126imp 7/10

Pipeline

Asset	Phase	Indication
ADG126 Mono	Phase 2	Advanced/Metastatic Solid Tumors
ADG126	Phase 2	Advanced/Metastatic Solid Tumors

Price & technical context

3-month

-33.1%

6-month

-18.4%

12-month

+58.4%

52-wk range

$1.40–$4.78

vs 50-day MA

-10.8%

vs 200-day MA

-4.1%

Realized vol

87.9%

Max drawdown

-60.2%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ADAG (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.